Pfizer Inc (PFE) reports robust financial performance with significant revenue growth and strategic progress in oncology and ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 ...

Pfizer faces stagnant revenue and patent cliffs. Learn why I downgraded PFE stock to Strong Sell despite a 24.7% YoY growth ...

"Our revenue volatility is largely in the past as COVID-related uncertainties have diminished," Pfizer's finance chief David ...

Pfizer Inc. shares fell 2% Tuesday despite the drugmaker topping Wall Street’s revenue and profit estimates in its ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

For 2025, Pfizer forecast revenue between $61 billion and $64 billion, as well as adjusted earnings per share in the range of $2.80 to $3.00. Analysts polled by FactSet expect $63.07 billion in ...

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...